Diabetes Research and Clinical Practice
Volume 90, Issue 1 , Pages 73-80 , October 2010

NF-κB binding activity and pro-inflammatory cytokines expression correlate with body mass index but not glycosylated hemoglobin in Chinese population

  • Lan He

      Affiliations

    • Department of Rheumatology, First Affiliated Hospital of Medical School, Xi’an Jiaotong University, 277 Yanta West Road, Xi’an, Shaanxi 710061, People's Republic of China
    • Corresponding Author InformationCorresponding author. Tel.: +86 29 8532 3975; fax: +86 29 8532 3979.
    • ,
  • Ming He

      Affiliations

    • Department of Rheumatology, First Affiliated Hospital of Medical School, Xi’an Jiaotong University, 277 Yanta West Road, Xi’an, Shaanxi 710061, People's Republic of China
    • ,
  • Xiaohong Lv

      Affiliations

    • Department of Rheumatology, First Affiliated Hospital of Medical School, Xi’an Jiaotong University, 277 Yanta West Road, Xi’an, Shaanxi 710061, People's Republic of China
    • ,
  • Dan Pu

      Affiliations

    • Department of Rheumatology, First Affiliated Hospital of Medical School, Xi’an Jiaotong University, 277 Yanta West Road, Xi’an, Shaanxi 710061, People's Republic of China
    • ,
  • Peihe Su

      Affiliations

    • Department of Rheumatology, First Affiliated Hospital of Medical School, Xi’an Jiaotong University, 277 Yanta West Road, Xi’an, Shaanxi 710061, People's Republic of China
    • ,
  • Zhiquan Liu

      Affiliations

    • Department of Cardiovascular Medicine, First Affiliated Hospital of Medical School, Xi’an Jiaotong University, 277 Yanta West Road, Xi’an, Shaanxi 710061, People's Republic of China

Received 29 March 2010 ,Revised 30 May 2010 ,Accepted 14 June 2010.

References 

  1. Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112(20):3066–3072
  2. Chen KW, Boyko EJ, Bergstrom RW, Leonetti DL, Newell-Morris L, Wahl PW, et al. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men. Diabetes Care. 1995;18(6):747–753
  3. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab. 2005;90(1):493–500
  4. Maedler K. Beta cells in type 2 diabetes—a crucial contribution to pathogenesis. Diabetes Obes Metab. 2008;10(5):408–420
  5. Meigs JB, Rutter MK, Sullivan LM, Fox CS, D’Agostino RB, Wilson PW. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care. 2007;30(5):1219–1225
  6. Tkác I. Metabolic syndrome in relationship to type 2 diabetes and atherosclerosis. Diabetes Res Clin Pract. 2005;68(S1):S2–S9
  7. Ansquer JC, Foucher C, Aubonnet P, Le Malicot K. Fibrates and microvascular complications in diabetes—insight from the FIELD study. Curr Pharm Des. 2009;15(5):537–552
  8. Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev. 2007;87(2):507–520
  9. Johansen OE. Cardiovascular disease and type 2 diabetes mellitus: a multifaceted symbiosis. Scand J Clin Lab Invest. 2007;67(8):786–800
  10. Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H, et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract. 2007;76(1):24–29
  11. Creely SJ, McTernan PG, Kusminski CM, Fisher FM, Da Silva NF, Khanolkar M, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;292(3):E740–E747
  12. Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol. 2008;8(12):923–934
  13. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27(3):813–823
  14. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, et al. Markers of inflammation and prediction of diabetes mellitus in adults (atherosclerosis risk in communities study): a cohort study. Lancet. 1999;353(9165):1649–1652
  15. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327–334
  16. Chen F, Castranova V, Shi X. New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol. 2001;159(2):387–397
  17. Nathan C. Points of control in inflammation. Nature. 2002;420(6917):846–852
  18. Li QT, Verma IM. NF-kappa B regulation in the immune system. Nat Rev Immunol. 2002;2(10):725–734
  19. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation. 2004;110(2):1564–1571
  20. Morigi M, Angioletti S, Imberti B, Donadelli R, Micheletti G, Figliuzzi M, et al. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kappa B-dependent fashion. J Clin Invest. 1998;101(9):1905–1915
  21. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106(16):2067–2072
  22. Rudofsky G, Reismann P, Schiekofer S, Petrov D, von Eynatten M, Humpert PM, et al. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappa B activation in PBMCs. Horm Metab Res. 2004;36(9):630–638
  23. Hofmann MA, Schiekofer S, Kanitz M, Klevesath MS, Joswig M, Lee V, et al. Insufficient glycemic control increases nuclear factor-kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care. 1998;21(8):1310–1316
  24. American Diabetes Association . Standards of medical care in diabetes-2007. Diabetes Care. 2007;30(S1):S4–S41
  25. World Health Organization Western Pacific Region and International Association for the Study of Obesity . The Asia-Pacific perspective: redefining obesity and its treatment. 2000;
  26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419
  27. Xu HY, Barnes GT, Yang Q, Tan Q, Yang DS, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821–1830
  28. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89(6):2548–2556
  29. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005;96(9):939–949
  30. Aljada A, Mohanty P, Ghanim H, Abdo T, Tripathy D, Chaudhuri A, et al. Increase in intranuclear nuclear factor kappa B and decrease in inhibitor-kappa B in mononuclear cells after a mixed meal: evidence for a proinflammatory effect. Am J Clin Nutr. 2004;79(4):682–690
  31. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappa B. Diabetes. 2001;50(12):2792–2808
  32. Nelson DE, Ihekwaba AE, Elliott M, Johnson JR, Gibney CA, Foreman BE, et al. Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science. 2004;306(5696):704–708
  33. Hoffmann A, Levchenko A, Scott ML, Baltimore D. The Ikappa B-NF-kappa B signaling module: temporal control and selective gene activation. Science. 2002;298(5596):1241–1245
  34. Li L, Sawamura T, Renier G. Glucose enhances human macrophage LOX-1 expression role for LOX-1 in glucose-induced macrophage foam cell formation. Circ Res. 2004;94(7):892–901
  35. Kern PA, Ranganathan S, Li CL, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280(5):E745–E751
  36. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4–12
  37. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115(5):1111–1119
  38. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42(5):987–1000
  39. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793–1801

PII: S0168-8227(10)00317-7

doi: 10.1016/j.diabres.2010.06.016

Diabetes Research and Clinical Practice
Volume 90, Issue 1 , Pages 73-80 , October 2010

Article Tools

* Image Usage & Resolution